BioCentury | May 27, 2020
Deals

Sanofi's sale of Regeneron stake for $11B could set stage for both companies' growth through M&A

More than 16 years and five product launches after closing its first deal with Regeneron, Sanofi has sold its holding of roughly 20% of the biotech's shares for about $11.1 billion. While the French pharma...
BioCentury | May 11, 2019
Product Development

Now grown up, independent biotechs bulk up their platforms with more modalities

As the incoming class of independent biotechs look to build on their clinical and commercial successes, a handful are expanding beyond the technology that got them there, bringing in new modalities to complement their platforms...
BioCentury | Aug 29, 2018
Distillery Therapeutics

Cancer

INDICATION: Cervical cancer; skin cancer Mouse studies suggest a vaccine based on a nanoparticle-HpV16gp2 peptide conjugate could help treat human papillomavirus (HPV)-associated cancers. The conjugate consists of nanoparticles with a polypropylene sulfide core and HpV16gp2...
BioCentury | May 25, 2018
Company News

Management tracks: ISA, ImCheck, ArQule

Immunotherapy company ISA Pharmaceuticals B.V. (Leiden, the Netherlands) promoted CBO Gerben Moolhuizen to CEO, effective June 1. He succeeds CEO Ronald Loggers. Also in May, ISA hired Leon Hooftman as CMO. Hooftman was CMO at...
BioCentury | Dec 22, 2017
Company News

Regeneron, ISA partner for HPV16-induced cancer combinations

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and ISA Pharmaceuticals B.V. (Leiden, the Netherlands) partnered to jointly conduct clinical trials evaluating ISA's ISA101 in combination with Regeneron's anti-PD-1 mAb cemiplimab (REGN2810, SAR439684) to treat cancer. ISA101 is an...
BioCentury | Dec 18, 2017
Company News

Regeneron, ISA partner for HPV16-induced cancer combinations

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and ISA Pharmaceuticals B.V. (Leiden, the Netherlands) partnered to jointly conduct clinical trials evaluating ISA's ISA101 in combination with Regeneron's anti-PD-1 mAb cemiplimab (REGN2810, SAR439684) to treat cancer. ISA101 is an...
BioCentury | Jul 20, 2017
Product R&D

Eureka moment for TCR mimics

In the race to access the wealth of intracellular molecular targets once considered undruggable, Eureka Therapeutics Inc. is pioneering TCR -like antibodies that capitalize on the ability of TCRs to recognize tumor antigens. But the...
BioCentury | Mar 16, 2017
Product R&D

Neo wave

The central thesis in the increasingly hot field of neoantigens is to pick mutations from patient tumors and turn them into personalized immunotherapies. While companies are staking out their space by defining how they will...
BioCentury | Dec 2, 2016
Company News

Parker Institute, CRI form neoantigen initiative

The Parker Institute for Cancer Immunotherapy and the Cancer Research Institute (New York, N.Y.) announced a partnership to improve algorithms used to identify cancer neoantigens. Nonprofit organization Sage Bionetworks (Seattle, Wash.) will manage bioinformatics and...
BioCentury | Dec 2, 2016
Company News

TESLA initiative launches

The Parker Institute for Cancer Immunotherapy and the Cancer Research Institute partnered to improve algorithms used to identify cancer neoantigens. Nonprofit organization Sage Bionetworks (Seattle, Wash.) will manage bioinformatics and data analysis for the project....
Items per page:
1 - 10 of 25
BioCentury | May 27, 2020
Deals

Sanofi's sale of Regeneron stake for $11B could set stage for both companies' growth through M&A

More than 16 years and five product launches after closing its first deal with Regeneron, Sanofi has sold its holding of roughly 20% of the biotech's shares for about $11.1 billion. While the French pharma...
BioCentury | May 11, 2019
Product Development

Now grown up, independent biotechs bulk up their platforms with more modalities

As the incoming class of independent biotechs look to build on their clinical and commercial successes, a handful are expanding beyond the technology that got them there, bringing in new modalities to complement their platforms...
BioCentury | Aug 29, 2018
Distillery Therapeutics

Cancer

INDICATION: Cervical cancer; skin cancer Mouse studies suggest a vaccine based on a nanoparticle-HpV16gp2 peptide conjugate could help treat human papillomavirus (HPV)-associated cancers. The conjugate consists of nanoparticles with a polypropylene sulfide core and HpV16gp2...
BioCentury | May 25, 2018
Company News

Management tracks: ISA, ImCheck, ArQule

Immunotherapy company ISA Pharmaceuticals B.V. (Leiden, the Netherlands) promoted CBO Gerben Moolhuizen to CEO, effective June 1. He succeeds CEO Ronald Loggers. Also in May, ISA hired Leon Hooftman as CMO. Hooftman was CMO at...
BioCentury | Dec 22, 2017
Company News

Regeneron, ISA partner for HPV16-induced cancer combinations

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and ISA Pharmaceuticals B.V. (Leiden, the Netherlands) partnered to jointly conduct clinical trials evaluating ISA's ISA101 in combination with Regeneron's anti-PD-1 mAb cemiplimab (REGN2810, SAR439684) to treat cancer. ISA101 is an...
BioCentury | Dec 18, 2017
Company News

Regeneron, ISA partner for HPV16-induced cancer combinations

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and ISA Pharmaceuticals B.V. (Leiden, the Netherlands) partnered to jointly conduct clinical trials evaluating ISA's ISA101 in combination with Regeneron's anti-PD-1 mAb cemiplimab (REGN2810, SAR439684) to treat cancer. ISA101 is an...
BioCentury | Jul 20, 2017
Product R&D

Eureka moment for TCR mimics

In the race to access the wealth of intracellular molecular targets once considered undruggable, Eureka Therapeutics Inc. is pioneering TCR -like antibodies that capitalize on the ability of TCRs to recognize tumor antigens. But the...
BioCentury | Mar 16, 2017
Product R&D

Neo wave

The central thesis in the increasingly hot field of neoantigens is to pick mutations from patient tumors and turn them into personalized immunotherapies. While companies are staking out their space by defining how they will...
BioCentury | Dec 2, 2016
Company News

Parker Institute, CRI form neoantigen initiative

The Parker Institute for Cancer Immunotherapy and the Cancer Research Institute (New York, N.Y.) announced a partnership to improve algorithms used to identify cancer neoantigens. Nonprofit organization Sage Bionetworks (Seattle, Wash.) will manage bioinformatics and...
BioCentury | Dec 2, 2016
Company News

TESLA initiative launches

The Parker Institute for Cancer Immunotherapy and the Cancer Research Institute partnered to improve algorithms used to identify cancer neoantigens. Nonprofit organization Sage Bionetworks (Seattle, Wash.) will manage bioinformatics and data analysis for the project....
Items per page:
1 - 10 of 25